Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: Data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study

Journal of Hypertension

Volumn 28, Issue 2, 2010, Pages 251-258

  Sciarretta, Sebastiano ^a   Valenti, Valentina ^a   Tocci, Giuliano ^a   Pontremoli, Roberto ^b   Rosei, Enrico Agabiti ^c   Ambrosioni, Ettore ^d   Costa, Vittorio ^d   Leonetti, Gastone ^e   Pessina, Achille Cesare ^f   Trimarco, Bruno ^g   Chin, Diana ^a   Paneni, Francesco ^a   Deferrari, Giacomo ^b   Ferrucci, Andrea ^a   Volpe, Massimo ^a,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Ospedale S Luca   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular risk; Hypertension; Renal damage; Risk charts

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACCURACY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBSERVATIONAL STUDY; PATIENT EDUCATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

EID: 75149151496     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283326718     Document Type: Article

References (19)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603.
3. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753.
4. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
5. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, De Leeuw PW, et al., Intervention as a Goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973-1980.
6. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, et al., Gruppo di Ricerca del Progetto CUORE. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita 2004; 40:393-399.
7. Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, et al. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2005; 16 (Suppl 1):S39-S41. (Pubitemid 41725081)
8. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21:1213-1220.
9. Böhm M, Thoenes M, Danchin N, Bramlage P, La Puerta P, Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25:2317-2324.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
11. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al., HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
12. Wachtell K, Ibsen H,Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
13. Sciarretta S, Pontremoli R, Rosei EA, Ambrosioni E, Costa V, Leonetti G, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2009; 27:410-417.
14. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14-18.
15. Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19:331-339.
16. Volpe M, Notaro LA, Tocci G, Panina G, Veglia F, Rosei EA. The REassessment of Antihypertensive Chronic Therapy (REACT) study: an Italian observational study on hypertension management of patients with established therapy. High Blood Press Cardiovasc Prev 2004; 11:175-185.
17. Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, Tocci G, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007; 20:784-791.
18. Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A, et al. Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 2008; 26:427-432.
19. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.